# US 2025/0372256 A1 · Ancestry-related kras co-alteration patterns as prognostic biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0372256 A1
- Document ID: US20250372256A1
- Status: Published application
- Kind: A1
- Application number: 19/224,407
- Filed: 2025-05-30
- Published: 2025-12-04
- Earliest claimed: 2024-06-04
- Assignees: Foundation Medicine, Inc.; Genentech, Inc.
- Applicants: Foundation Medicine, Inc.; Genentech, Inc.
- Inventors: Saumya Dushyant SISOUDIYA; Ethan S. SOKOL; Smruthy K. SIVAKUMAR; Zhen SHI; Gaurav PATHRIA
- Web page: https://patentgrep.com/patent/US20250372256A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Biomarker-based methods for predicting disease prognosis and treatment outcomes are described. In some instances, the disclosed methods can comprise, for example, detecting in a sample from the subject, a KRAS gene alteration; detecting, in the sample from the subject, at least one of a STK11 gene alteration or a KEAP1 gene alteration; and predicting a prognosis and/or treatment outcome for the subject based on the detection of a co-alteration of the KRAS gene and at least one of the STK11 and/or KEAP1 genes. In some instances, the disease may be cancer, e.g., non-squamous non-small cell lung cancer (NSCLC). In some instances, the prediction of treatment outcomes may comprise prediction of treatment outcomes when treating a cancer (e.g., NSCLC) with an immune checkpoint inhibitor (ICI) or a KRAS G12C inhibitor.

## Claims

### Claim 1

A method for diagnosing or confirming a diagnosis of disease in a subject, the method comprising:
providing a plurality of nucleic acid molecules obtained from a sample from a subject;
ligating one or more adapters onto one or more nucleic acid molecules from the plurality of nucleic acid molecules;
amplifying the one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules;
capturing amplified nucleic acid molecules from the amplified nucleic acid molecules;
sequencing, by a sequencer, the captured nucleic acid molecules to obtain a plurality of sequence reads that represent the captured nucleic acid molecules;
receiving, using one or more processors, sequence read data for the plurality of sequence reads;
detecting, using the one or more processors, a KRAS gene alteration in the sample from the subject based on the sequence read data;
detecting, using the one or more processors, at least one of a STK11 gene alteration or a KEAP1 gene alteration in the sample from the subject based on the sequence read data; and
diagnosing or confirming a diagnosis of disease in the subject based on the detection of a co-alteration of the KRAS gene and at least one of the STK11 and/or KEAP1 genes.

### Claim 2

A method for predicting a treatment outcome for a subject diagnosed with or suspected of having a disease, the method comprising:
detecting, in a sample from the subject, a KRAS gene alteration;
detecting, in the sample from the subject, at least one of a STK11 gene alteration or a KEAP1 gene alteration; and
predicting a treatment outcome for the subject based on the detection of a co-alteration of the KRAS gene and at least one of the STK11 and/or KEAP1 genes.

### Claim 3 (depends on 2)

The method of claim 2, wherein the disease is cancer, and optionally, wherein the cancer is non-squamous non-small cell lung cancer (NSCLC).

### Claim 4 (depends on 2)

The method of claim 2, wherein the predicted outcome for the subject is poor compared to that for a sample in which only a KRAS gene alteration is detected.

### Claim 5 (depends on 2)

The method of claim 2, further comprising detecting at least one biomarker of genetic ancestry in the sample from the subject, and adjusting the predicted treatment outcome based on the detection of the at least one biomarker of genetic ancestry.

### Claim 6 (depends on 5)

The method of claim 5, wherein the at least one biomarker of genetic ancestry is indicative of European, African, East Asian, South Asian, and admixed American ancestry.

### Claim 7 (depends on 5)

The method of claim 5, wherein the at least one biomarker of genetic ancestry comprises a single nucleotide polymorphism (SNP)-based biomarker.

### Claim 8 (depends on 5)

The method of claim 5, further comprising detecting a co-occurrence of a KRAS gene alteration and a GNAS gene alteration in a sample from a subject for which the at least one biomarker of genetic ancestry is indicative of admixed American ancestry, and adjusting the predicted treatment outcome based on the detection of the GNAS gene alteration.

### Claim 9 (depends on 5)

The method of claim 5, further comprising detecting a co-occurrence of a KRAS gene alteration and an ARID1A gene alteration in a sample from a subject for which the at least one biomarker of genetic ancestry is indicative of South Asian ancestry, and adjusting the predicted treatment outcome based on the detection of the ARID1A gene alteration.

### Claim 10 (depends on 5)

The method of claim 5, further comprising a tumor mutational burden (TMB) in a sample from a subject for which the at least one biomarker of genetic ancestry is indicative of African, and adjusting the predicted treatment outcome based on the determined TMB.

### Claim 11 (depends on 1)

The method of claim 1, wherein the KRAS gene alteration comprises a KRAS short variant, a KRAS gene amplification, or any combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the KRAS gene alteration comprises a KRAS G12C alteration.

### Claim 13 (depends on 1)

The method of claim 1, wherein the STK11 and/or KEAP1 gene alterations comprise loss-of-function alterations.

### Claim 14 (depends on 1)

The method of claim 1, wherein the disease is cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cancer is non-squamous non-small cell lung cancer (NSCLC).

### Claim 16 (depends on 1)

The method of claim 1, wherein treatment of the disease comprises treatment with an immune checkpoint inhibitor (ICI).

### Claim 17 (depends on 1)

The method of claim 1, wherein treatment of the disease comprises treatment with a KRAS G12C inhibitor.

### Claim 18 (depends on 1)

The method of claim 1, further comprising: (i) identifying the subject for treatment of a disease, (ii) predicting a prognosis for the subject, (iii) selecting a treatment for the subject, (iv) treating the subject, (v) adjusting a treatment dose for the subject, (vi) identifying the subject for inclusion in a clinical trial, or (vii) monitoring the disease progression or recurrence in the subject, based on the detection of a co-alteration of the KRAS gene and at least one of the STK11 and/or KEAP1 genes.

### Claim 19

A system comprising:
one or more processors; and
a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to:
receive sequence read data for a plurality of sequence reads derived from a sample from a subject;
detect a KRAS gene alteration in the sample from the subject based on the sequence read data;
detect at least one of a STK11 gene alteration or a KEAP1 gene alteration in the sample from the subject based on the sequence read data; and
diagnose or confirm a diagnosis of disease in the subject based on the detection of a co-alteration of the KRAS gene and at least one of the STK11 and/or KEAP1 genes.
